The summit arrives as the landscape for Limb-Girdle Muscular Dystrophy shifts toward regenerative medicine and patient-focused drug development. Sessions will tackle technical hurdles in biomarker qualification and natural history studies, while a dedicated panel featuring U.S. Food and Drug Administration representatives will focus on refining clinical trial designs for rare neuromuscular diseases.
Key scientific leaders, including Douglas Sproule of BridgeBio Neuromuscular and Louise Rodino-Klapac of Sarepta Therapeutics, headline the event. They will be joined by researchers from institutions like the University of Copenhagen and Charité – Universitätsmedizin Berlin to discuss strategies for ensuring no LGMD subtype is overlooked during this period of rapid innovation. Representatives from biotech firms such as AskBio, Genethon, and MyoPax will also present updates on their current pipelines.
Nicholas Johnson, a professor at Virginia Commonwealth University, noted that the current pace of discovery has created possibilities that were unreachable a decade ago. Registration for the virtual summit is currently open to patients, clinicians, and industry professionals via the organization’s official portal.
Comments (0)
No comments yet. Be the first!